Be Biopharma

Be Bio is headed to London! Our team looks forward to joining leading global, public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors at Jefferies London Healthcare Conference 2024 taking place November 19–21. This year’s gathering marks the 15th anniversary of the largest healthcare-dedicated conference in Europe and will bring together leading executives to address near-and long-term investment opportunities as well as the current trends driving healthcare in the U.S. and internationally. #BeBio #Healthcare #Innovation #JefferiesHealthcare

This Veterans Day, Be Bio proudly recognizes the dedication and courage of those who have served our country. Today, and everyday, we are grateful for your service. To all Veterans, thank you! #VeteransDay #BeBio

Be Bio will present at the 66th American Society of Hematology (ASH) Annual Meeting! Join us for our oral presentation titled, "A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics (Abstract #88)," on Dec 7 at 10:15am PT in the San Diego Convention Center, Ballroom 20AB. A Trials in Progress abstract for the BeCoMe-9 Phase 1/2 clinical trial for BE-101 in hemophilia B has also been accepted for online publication. Full press release here:?https://lnkd.in/ebdjP2wp #ASH24 #BeBio #BCellMedicines

We're honored to be recognized by Nasdaq for our $82M financing! All proceeds will fund our mission to develop a new class of B cell medicines that have the potential to improve the lives of people living with rare and prevalent diseases. Our first clinical trial, BeCoMe-9 for Hemophilia B, is now open and enrolling patients. #BeBio #Nasdaq?#Innovation #BCellMedicines

We are thrilled to announce that we are now enrolling patients in the BeCoMe-9 Phase I/II trial for people with Hemophilia B. Our mission is to develop transformative medicines that have the potential to improve the lives of people living with rare and prevalent disease, and this milestone brings us one step closer to doing just that. ? With the launch of this trial for BE-101, bolstered by fresh capital from our recent $82M funding round, the addition of seasoned clinical and commercial leaders Suha Patel and Kiran C. Patki, MD, MSc, FFPM, and a new development candidate for Hypophosphatasia following closely behind, we are making significant strides toward our goal to improve countless patient stories. ? Stay tuned for more updates as we continue this journey! ? Read more in our press release: https://lnkd.in/ez6DRUxH. #Hemophilia #ClinicalTrials #Hypophosphatasia #Biotech #Innovation #TransformingLives #BeBio #BCellMedicines

Be Bio’s headed to Italy! We’re excited to share that we’ll be presenting at the European Society of Gene and Cell Therapy (ESGCT) conference in Rome, Oct 22-Oct 25. Join us for the following poster presentations: “Development of precision gene engineered B cells as a treatment for hemophilia B“ “CRISPR/Cas9-based precision B cell gene engineering produces active tissue nonspecific alkaline phosphatase for the potential treatment of hypophosphatasia” Learn more at esgctcongress.com/. See you there! #BeBio #ESCGT

Be Bio proudly participated in the New England Hemophilia Association’s 15th annual Unite for Bleeding Disorders Walk. Through our team’s fundraising efforts, we raised over $9,000 to support local communities. We’re honored to do our part in supporting those living with Hemophilia B as we progress in the development of BE-101. “I am excited to have participated in this event and look forward to upcoming opportunities for the Be Bio team to deepen our connections with the vibrant Hemophilia community." – Joanne Smith-Farrell, Ph.D. #BeBio #HemophiliaB

Join us at the 2024 Cell & Gene Meeting on the Mesa! Hear Be Bio’s CEO Joanne Smith-Farrell’s presentation on Oct 8, 3:30pm ET. We look forward to seeing you there! #MeetingOnTheMesa #BeBio?

ICYMI: Be Bio recently shared new preclinical data for the potential treatment of Hypophosphatasia at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. “This study builds on data presented earlier this year, demonstrating the ability of BCMs to produce sustained active levels of ALP in vivo,” said Rick Morgan, Ph.D. Read the full press release here: https://lnkd.in/g3Aba9UC. #ASBMR #BCellMedicines #BeBio

Join us in Boston! Our CEO Joanne Smith-Farrell will be participating in a panel discussion “Gene and Cell Therapy’s Unlimited Potential” at the World Medical Innovation Forum in Boston, Sept 23 at 11:00am ET. #BeBio #WMIF2024